Sciclone Pharmaceuticals (SCLN) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 05, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	scln
Entity Registrant Name	SCICLONE PHARMACEUTICALS INC
Entity Central Index Key	880,771
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		49,376,787

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 99,224	$ 86,228
Accounts receivable, net of allowances of $1,137 and $998 as of September 30, 2015 and December 31, 2014, respectively	40,210	40,268
Inventories	12,147	10,703
Short-term investments		75
Prepaid expenses and other current assets	1,933	2,597
Deferred tax assets	306	326
Total current assets	153,820	140,197
Property and equipment, net	2,219	1,848
Goodwill	33,686	34,521
Other assets	12,507	5,265
Total assets	202,232	181,831
Current liabilities:
Accounts payable	3,803	5,311
Accrued and other current liabilities	32,188	20,536
Deferred revenue	203	596
Total current liabilities	36,194	26,443
Other long-term liabilities	$ 33	$ 114
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock; $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock; $0.001 par value; 100,000,000 shares authorized; 49,374,287 and 49,948,897 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 49	$ 50
Additional paid-in capital	294,349	287,108
Accumulated other comprehensive income	2,646	3,264
Accumulated deficit	(131,039)	(135,148)
Total stockholders' equity	166,005	155,274
Total liabilities and stockholders' equity	$ 202,232	$ 181,831

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets [Abstract]
Allowance for doubtful accounts	$ 1,137	$ 998
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	49,374,287	49,948,897
Common stock, shares outstanding	49,374,287	49,948,897

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product sales, net	$ 41,986	$ 33,621	$ 112,356	$ 91,236
Promotion services	894	666	2,038	2,129
Total net revenues	42,880	34,287	114,394	93,365
Operating expenses:
Cost of product sales	6,853	6,005	17,131	15,577
Sales and marketing	15,077	13,911	39,098	34,987
Research and development	1,039	653	8,708	2,933
General and administrative	7,290	5,611	21,410	17,460
Estimated settlement expense (Note 9)	26		10,826
Total operating expenses	30,285	26,180	97,173	70,957
Income from operations	12,595	8,107	17,221	22,408
Non-operating income (expense):
Interest and investment income	252	31	614	73
Interest and investment expense				(48)
Other income (expense), net	(281)	108	(305)	19
Income before provision for income tax	12,566	8,246	17,530	22,452
Provision for income tax	587	331	611	763
Net income	$ 11,979	$ 7,915	$ 16,919	$ 21,689
Basic net income per share	$ 0.24	$ 0.16	$ 0.34	$ 0.42
Diluted net income per share	$ 0.23	$ 0.15	$ 0.32	$ 0.41
Weighted average shares used in computing:
Basic net income per share	49,869	51,032	49,920	51,533
Diluted net income per share	52,126	52,393	52,344	52,799

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Consolidated Statements Of Comprehensive Income (Loss) [Abstract]
Net income	$ 11,979	$ 7,915	$ 16,919	$ 21,689
Other comprehensive (loss) income, net of income tax
Foreign currency translation	(661)	308	(618)	(466)
Total other comprehensive (loss) income	(661)	308	(618)	(466)
Total comprehensive income	$ 11,318	$ 8,223	$ 16,301	$ 21,223

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities:
Net income	$ 16,919	$ 21,689
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash expense related to stock-based compensation	3,437	2,609
Provision for doubtful accounts	541
Provision for expiring inventory		990
Depreciation and amortization	802	652
Loss on disposal of fixed assets	2	17
Deferred income taxes	12
Changes in operating assets and liabilities:
Accounts receivable, net	(526)	3,307
Inventories	1,215	4,240
Prepaid expenses and other assets	692	627
Accounts payable	(4,076)	(5,365)
Accrued and other current liabilities	11,822	(2,006)
Deferred revenue	(394)	(256)
Other long-term liabilities	(80)	(50)
Net cash provided by operating activities	30,366	26,454
Investing activities:
Loans to third party (Note 4)	(7,250)	(2,501)
Proceeds from the sale of short-term investments	75
Purchases of property and equipment	(1,152)	(1,065)
Net cash used in investing activities	(8,327)	(3,566)
Financing activities:
Repurchase of common stock including commissions	(12,811)	(14,179)
Repayment of credit facility		(1,619)
Proceeds from issuances of common stock, net	3,696	3,989
Net cash used in financing activities	(9,115)	(11,809)
Effect of exchange rate changes on cash and cash equivalents	72	(51)
Net increase in cash and cash equivalents	12,996	11,028
Cash and cash equivalents, beginning of period	86,228	85,803
Cash and cash equivalents, end of period	$ 99,224	$ 96,831

Basis Of Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2015
Basis Of Presentation [Abstract]
Basis Of Presentation	Note 1 — Basis of Presentation The accompanying unaudited condensed consolidated financial statements of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the audited consolidated financial statements and the notes thereto for the year ended December 31, 2014 included in the Company’s Form 10-K as filed with the US Securities and Exchange Commission (“SEC”). The Company prepared the unaudited condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other information that are normally required by GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The interim financial information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited condensed consolidated balance sheet data as of December 31, 2014 is derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ significantly from those estimates. Revisions The Company reduced the line item “Inventories” and increased the line item “Provision for expiring inventory” in the amount of $0.4 million within the reconciling adjustments in its condensed consolidated statement of cash flows for the nine months ended September 30, 2014 to correct an error in the prior year presentation. This revision had no impact on cash provided by operating activities. For the full year 2014, the line item “Inventories” was overstated and the line item “Provision for expiring inventory” was understated by $0.5 million within the reconciling adjustments in its consolidated statement of cash flows as presented for the year ended December 31, 2014 included in the Company’s Form 10-K as filed with the SEC. The amounts of the errors are not material to the annual or interim periods of 2014. Customer Concentration In China, pharmaceutical products are imported and distributed through a tiered method of distribution. For the Company’s proprietary product ZADAXIN ® , the Company manufactures its product using its US and European contract manufacturers, and it generates its product sales revenue through sales of ZADAXIN products to Sinopharm Holding Hong Kong Co. Ltd. (“Sinopharm”). Sinopharm and its affiliates act as an importer, and also as the top “tier” of the distribution system (“Tier 1”) in China. The Company’s ZADAXIN sales occur when the importer purchases product from the Company, without any right of return except for damaged product or quality control issues and passage of title and risk of loss are transferred to Sinopharm at the time of shipment. After the Company’s sale of ZADAXIN to the importer, Sinopharm clears products through China import customs, sells directly to large hospitals and holds additional product it has purchased in inventory for sale to the next tier in the distribution system. The second-tier (“Tier 2”) distributors are responsible for the further sale and distribution of the products they purchase from the importer, either through sales of product directly to the retail level (hospitals and pharmacies), or to third-tier (“Tier 3”) local or regional distributors who, in turn, sell products to hospitals and pharmacies. The Company’s other product sales revenues result from the sale of the Company’s in-licensed products to importing agents and distributors. Promotion services revenues result from fees received for exclusively promoting products for certain pharmaceutical partners. These importing agents, distributors and partners are the Company’s customers. Sinopharm revenues relate to the Company’s China segment. Sinopharm contributed 98% and 94% of the Company’s total net revenue for the three-month periods ended September 30, 2015 and 2014, respectively. Sinopharm contributed 92% and 93% of the Company’s total net revenue for the nine-month periods ended September 30, 2015 and 2014, respectively. There were no other customers that exceeded 10% of the Company’s total net revenue in the periods presented. As of September 30, 2015, approximately $ 37.4 million, or 91% , of the Company's accounts receivable was attributable to one customer, Sinopharm, in China. The Company generally does not require collateral from its customers. Accounts Receivable Receivable Reserve. The Company records a receivable reserve based on a specific review of its overdue invoices. The Company’s estimate for a reserve is determined after considering its existing contractual payment terms, payment patterns of its customers and individual customer circumstances, the age of any outstanding receivables and its current customer relationships. Accounts receivable are written off at the point when they are considered uncollectible. As of September 30, 2015, the Company had a receivable reserve of $1.1 million. The reserve includes $0.5 million from one customer that is more than one year past due. In October 2014, the Company’s subsidiary, SciClone Pharmaceuticals International China Holding Ltd (“SPIL China”) executed an agreement with this particular customer providing for settlement of the receivable balance, which at the time was $1.9 million, of which $1.0 million was paid in 2014. The remaining $0.9 million was scheduled to be paid in installments as follows: (i) $0.4 million before May 31, 2015, and (ii) $0.5 million by December 31, 2015. The Company collected $0.4 million in May 2015, and this gain on recovery was recorded as a $0.4 million reduction to general and administrative expense for the nine-month period ended September 30, 2015. The Company will continue to maintain a full reserve on the remaining $0.5 million outstanding accounts receivable balance from this customer until payment is received. As of September 30, 2015, the Company had $0.5 million in fully reserved accounts receivable from another customer that are past due. The Company recognized $0.5 million of bad debt expense in general and administrative expense during the first quarter of 2015 due to uncertainty regarding the collectability of the customer’s outstanding receivable balance. Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, services have been rendered or delivery has occurred, the price to the buyer is fixed or determinable and collectability is reasonably assured. Product Revenue . The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN to Sinopharm and its affiliates are recognized at time of shipment when title to the product is transferred to them. The Company also earns product revenue from purchasing medical products from pharmaceutical companies and selling them directly to importers or distributors. The Company recognizes revenue related to these products based on the “sell-in” method, when the medical products have been delivered to the importers or distributors. Payments by the importing agents and distributors are not contingent upon sale to the end user by the importing agents or distributors. Promotion Services Revenue . The Company recognizes promotion services revenue after designated medical products are delivered to the distributors as specified in a promotion services contract, which marks the period when marketing and promotion services have been rendered and the revenue recognition criteria are met. Revenue Reserve. The Company generally maintains a revenue reserve for product returns based on estimates of the amount of product to be returned by its customers which may result from expired or damaged product on delivery, and is based on historical patterns, analysis of market demand and/or a percentage of sales based on industry trends, and management’s evaluation of specific factors that may increase the risk of product returns. Importing agents or distributors do not have contractual rights of return except under limited terms regarding product quality. However, the Company is expected to replace products that have expired or are deemed to be damaged or defective when delivered. The calculation of the revenue reserve requires estimates and involves a high degree of subjectivity and judgment. As a result of the uncertainties involved in estimating the revenue reserve, there is a possibility that materially different amounts could be reported under different conditions or using different assumptions. As of September 30, 2015 and December 31, 2014, the Company’s revenue reserves were $0.6 million and $0. 1 million, respectively. Inventories Inventories consist of raw materials, work in progress and finished products. Inventories are valued at the lower of cost or market (net realizable value), with cost determined on a first-in, first-out basis, and include amounts related to materials, labor and overhead. The Company periodically reviews the inventory in order to identify excess and obsolete items, including pharmaceutical products approaching their expiration dates. If obsolete or excess items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value. For the three- and nine-month periods ended September 30, 2015, the Company recorded no inventory write-downs. For the three- and nine-month periods ended September 30, 2014, the Company recorded inventory write-downs of $0.6 million and $1.0 million, respectively, related to carrying value reductions for excess Aggrastat ® product. Loans Receivable Loans receivable are due from a single third party (see Note 4). Loans are initially recorded, and continue to be carried, at unpaid principal balances under “other assets” on the unaudited condensed consolidated balance sheet. Carried balances are subsequently adjusted for payments of principal or adjustments to the allowance for loan losses to account for any impairment. Interest income is recognized over the term of the loans and is calculated using the simple-interest method, as the loans do not have associated premium or discount. If the loans were to experience impairment, interest income would not be recognized unless the likelihood of further loss was remote. Although the measurement basis is unpaid principal (as adjusted for subsequent payments or impairment), not fair value, the loans receivable would qualify as Level 3 measurements under the fair value hierarchy (Note 2) due to the presence of significant unobservable inputs related to the counterparty, which is a private entity. Management considers impairment to exist when, based on current information or factors (such as payment history, value of collateral, and assessment of the counterparty’s current creditworthiness), it is probable that principal and interest payments will not be collected according to the contractual agreements. Management considers a loan payment delinquent when not received by the due date. As of September 30, 2015 and December 31, 2014, management concluded the loans receivable were not impaired, and there was no allowance for loan losses. Net Income Per Share Basic net income per share has been computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted net income per share is computed by dividing net income by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income per share includes any dilutive impact from outstanding stock options, restricted stock units (RSUs), performance restricted stock units (PSUs) and the employee stock purchase plan using the treasury stock method. The following is a reconciliation of the numerator and denominators of the basic and diluted net income per share computations (in thousands, except per share amounts): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Numerator: Net income $ $ $ $ Denominator: Weighted-average shares outstanding used to compute basic net income per share Effect of dilutive securities Weighted-average shares outstanding used to compute diluted net income per share Basic net income per share $ $ $ $ Diluted net income per share $ $ $ $ For the three months ended September 30, 2015 and 2014, outstanding stock options for 1,514,534 and 3,733,555 shares, respectively, were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options calculated under the treasury stock method would have been anti-dilutive. In addition, for the three months ended September 30, 2015 and 2014, outstanding stock options and awards for 312,500 and 50,000 shares, respectively, subject to performance conditions were excluded from the calculation of diluted net income per share because the performance criteria had not been met. For the nine months ended September 30, 2015 and 2014, outstanding stock options for 1,043,815 and 3,924,745 shares, respectively, were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options calculated under the treasury stock method would have been anti-dilutive. In addition, for the nine months ended September 30, 2015 and 2014, outstanding stock options and awards for 325,137 and 50,000 shares, respectively, subject to performance conditions were excluded from the calculation of diluted net income per share because the performance criteria had not yet been met. New Accounting Standards Updates In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 is effective for the Company’s fiscal year beginning January 1, 2018, which reflects a one year deferral approved by the FASB in July 2015, with early application permitted provided that the effective date is not earlier than the original effective date. The Company is in the process of determining what impact, if any, the adoption of ASU 2014-09 will have on its financial statements and related disclosures. The standard permits the use of either the full retrospective or modified retrospective transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In July 2015, the FASB issued ASU 2015-11, " Inventory (Topic 330): Simplifying the Measurement of Inventory " (“ASU 2015-11”) which applies to inventory that is measured using first-in, first-out ("FIFO") or average cost. Under the updated guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory that is measured using last-in, first-out ("LIFO"). This ASU is effective for annual and interim periods beginning after December 15, 2016, and should be applied prospectively with early adoption permitted at the beginning of an interim or annual reporting period. The Company has evaluated the impact of adopting this guidance and has concluded it will likely have minimal effect on the financial statements as the Company already applies the concept of net realizable value; moreover, inventory provisions are generally full write-downs for the affected inventory.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 2 — Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. The three levels of input are: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following tables represent the Company’s fair value hierarchy for its financial assets (cash equivalents and short-term investments) measured at fair value on a recurring basis ( in thousands ): Fair Value Measurements as of September 30, 2015 Using Quoted Prices in Significant Active Markets Other Significant for Observable Unobservable Balance Identical Assets Inputs Inputs as of Description (Level 1) (Level 2) (Level 3) September 30, 2015 Money market funds $ $ — $ — $ Total $ $ — $ — $ Fair Value Measurements as of December 31, 2014 Using Quoted Prices in Significant Active Markets Other Significant for Observable Unobservable Balance Identical Assets Inputs Inputs as of Description (Level 1) (Level 2) (Level 3) December 31, 2014 Certificate of deposit $ — $ $ — $ Money market funds — — Total $ $ $ — $

Inventories

Inventories	9 Months Ended
	Sep. 30, 2015
Inventories [Abstract]
Inventories	Note 3 — Inventories Inventories consisted of the following (in thousands): September 30, December 31, 2015 2014 Raw materials $ $ Work in progress Finished goods $ $ Included in the Company’s inventory as of September 30, 2015 and December 31, 2014, was $ 3.6 million and $ 3.1 million, respectively, in inventory held at distributors related to products sold by its NovaMed Pharmaceuticals, Inc. and NovaMed Pharmaceuticals (Shanghai) Co. Ltd. subsidiaries.

Loans Receivable

Loans Receivable	9 Months Ended
	Sep. 30, 2015
Loans Receivable [Abstract]
Loans Receivable	Note 4 — Loans Receivable As part of the Company’s May 2013 license and supply agreement with Zensun (Shanghai) Science & Technology Co. Ltd (“Zensun”), the Company previously agreed to loan up to $12 million to Zensun. The entry into the license and supply agreement in the second quarter of 2013, pursuant to which the Company licensed the exclusive rights to promote, market, distribute, and sell Neucardin TM , a chronic heart failure product under development by Zensun (such rights licensed for the People’s Republic of China, Hong Kong and Macau) is more fully described in the Company’s quarterly report on Form 10-Q for the second quarter of 2013. Pursuant to its agreement to loan funds, the Company loaned $12 million to Zensun. The extension of credit and funding to Zensun was accomplished through two of the Company's subsidiaries, SPIL China and SciClone Pharmaceuticals (China) Ltd. (“SciClone China”). With respect to lender SciClone China, Zensun could request RMB-denominated borrowings for up to RMB 1,550,000 using an entrustment mechanism with a bank as an intermediary. In the third quarter of 2014, SciClone China entered into an entrusted loan agreement for RMB 1,550,000 (approximately US $244,000 as of September 30, 2015) with Zensun, using a major Chinese bank as the lending agent. SciClone China is the principal and ultimately bears the credit risk, not the bank. The loan bears interest at a fixed rate of 7.5% per annum, with interest payable quarterly, and Zensun is subject to obligations of the borrower as specified in the loan agreements. The loan term is sixty-six months. All outstanding principal and interest balances must be repaid by the maturity date, with prepayments permitted without penalty upon prior notice. With respect to lender SPIL China, Zensun could request US-dollar denominated borrowings up to $11.75 million. As of September 30, 2015, borrowings totaling $11.75 million had been requested by Zensun and paid by SPIL China with $4.5 million lent in the second half of 2014 and $7.25 million lent in the second quarter of 2015. These borrowings bear interest at a fixed rate of 7.5% per annum payable annually in arrears at each interest payment date as defined in the agreement. These borrowings mature on September 26, 2017 , with an option electable by the borrower to extend for two additional years provided certain conditions are met. All outstanding balances must be repaid by the maturity date, with prepayments permitted without penalty upon prior notice. The proceeds of the two separate but related loans are to be used for working capital and general corporate purposes by Zensun. To secure the loans, Zensun pledged its entire equity interest in its subsidiary, Shanghai Dongxin Biochemical Technology Co. Ltd. (whose assets include real property) to SPIL China. Management, on the basis of (i) a creditworthiness evaluation using recent Zensun financial information, (ii) consideration of the market value of the pledged security, and (iii) consideration of Zensun’s compliance with the terms of the loans and timely payment of interest, concluded there were no indications of loan impairment as of September 30, 2015 or December 31, 2014; accordingly, there is no allowance for loan losses. The two loans are included in “other assets” on the Company’s unaudited condensed consolidated balance sheet as of September 30, 2015 and December 31, 2014. Interest income on the loans amounted to $0.2 million and $0.5 million for the three- and nine-months ended September 30, 2015, respectively, and is included in interest and investment income in the unaudited condensed consolidated statements of income.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2015
Goodwill [Abstract]
Goodwill	Note 5 — Goodwill The following table represents the changes in goodwill for the nine months ended September 30, 2015 ( in thousands ): Balance as of December 31, 2014 $ Translation adjustments Balance as of September 30, 2015 $

Accrued And Other Current Liabi

Accrued And Other Current Liabilities	9 Months Ended
	Sep. 30, 2015
Accrued And Other Current Liabilities [Abstract]
Accrued And Other Current Liabilities	Note 6 — Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): September 30, December 31, 2015 2014 Accrued estimated settlement expense (Note 9) $ $ Accrued sales and marketing expenses Accrued taxes, tax reserves and interest Accrued compensation and benefits Accrued professional fees Accrued manufacturing costs Accrued license fee — Other $ $

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	Note 7 — Accumulated Other Comprehensive Income Changes in the composition of accumulated other comprehensive income (loss) for the three- and nine-months ended September 30, 2015 and 2014 are as follows ( in thousands ): Balances as of July 1, 2015 $ Other comprehensive loss related to foreign currency translation Balances as of September 30, 2015 $ Balances as of July 1, 2014 $ Other comprehensive income related to foreign currency translation Balances as of September 30, 2014 $ Balances as of January 1, 2015 $ Other comprehensive loss related to foreign currency translation Balances as of September 30, 2015 $ Balances as of January 1, 2014 $ Other comprehensive loss related to foreign currency translation Balances as of September 30, 2014 $

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 8 — Stockholders’ Equity Stock-based Compensation The following table summarizes the stock-based compensation expenses included in the unaudited condensed consolidated statements of income ( in thousands ): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Sales and marketing $ $ $ $ Research and development General and administrative $ $ $ $ Stock Options During the nine months ended September 30, 2015, the Company granted options to purchase a total of 1,375,500 shares of common stock and options to purchase 868,682 shares of common stock were exercised. As of September 30, 2015, there was approximately $6.4 million of unrecognized compensation expense, net of forfeitures, related to non-vested stock options, which is expected to be recognized over a weighted-average remaining period of approximately 2.60 years. RSUs and PSUs During the nine months ended September 30, 2015, 388,000 RSUs and 300,000 PSUs were granted at a weighted-average grant date fair value per share of $ 8.95 , and 105,517 RSUs were released. The PSUs will vest and be released on meeting performance goals (including revenue and product expansion targets) within an established time frame. If the performance goals are not met within the established time frame, the PSUs will expire. The Company recognizes expense related to the PSUs over the implicit service period if it is probable that the performance goals will be achieved. If it is subsequently determined that the performance goals are not probable of achievement, the expense related to the PSUs is reversed. For the three- and nine-month periods ended September 30, 2015, the Company recorded approximately $31,000 and $60,000 , respectively, of expense related to the PSUs. As of September 30, 2015, there was approximately $ 2.5 million of unrecognized compensation cost, net of forfeitures, related to non-vested RSUs and PSUs, which is expected to be recognized over a weighted-average remaining period of approximately 2.35 years. Repurchase of Common Stock The Company repurchased and retired 1,526,306 shares at a cost of $12.8 million during the nine-month period ended September 30, 2015. As of September 30, 2015, $2.4 million of the $80.5 million share repurchase program authorized by the Board of Directors was available for future share repurchases. Repurchased shares have been retired and constitute authorized but unissued shares.

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies [Abstract]
Commitments And Contingencies	Note 9 —Commitments and Contingencies Legal Matters The Company is a party to various legal proceedings and subject to government investigations, as noted in this section below. All legal proceedings and any government investigations are subject to inherent uncertainties, unfavorable rulings or other adverse events which could occur. Unfavorable outcomes could include substantial monetary damages or awards, injunctions or other remedies, and if any of these were to occur, the possibility exists for a material adverse impact on the Company’s business, results of operations, financial position, and overall trends. The Company might also conclude that settling one or more such matters is in the best interests of its stockholders and its business, and any such settlement could include substantial payments. As previously disclosed, since 2010 the SEC and the US Department of Justice (“DOJ”) have each been conducting formal investigations of the Company regarding a range of matters, including the possibility of violations of the Foreign Corrupt Practices Act (“FCPA”), primarily related to certain historical sales and marketing activities with respect to the Company’s China operations. In response to these matters, the Company’s Board appointed a Special Committee of independent directors (the “Special Committee”) to oversee its response to the government inquiry. Based on an initial review, the Special Committee decided to undertake an independent investigation as to matters reflected in and arising from the SEC and DOJ investigations in order to evaluate whether any violation of the FCPA or other laws occurred. The Company continues to cooperate fully with the SEC and DOJ in the conduct of their investigations. The Company has engaged in settlement discussions with the SEC related to its investigation into possible violations of the FCPA by the Company. The Company has finalized the terms of an offer of settlement of these matters, subject to final approval by the Commissioners of the SEC. Under the terms of the offer of settlement, the Company, without admitting or denying liability, would consent to the entry of an administrative order requiring that the Company cease and desist from any future violations of the FCPA. The Company also would pay disgorgement of $9.4 million, prejudgment interest of $0.9 million and a civil money penalty of $2.5 million. If the offer of settlement is approved by the Commissioners of the SEC, an administrative order will be issued by the SEC and $12,826,000 (which was placed in an escrow facility subsequent to September 30, 2015) will immediately be released to the SEC. The Company has not yet reached a resolution of these matters with the DOJ and management continues to work diligently to obtain closure on this matter. The Company previously recorded a charge of $2.0 million in the fourth quarter of 2013 related to the possibility of a settlement, and recorded additional charges of $10.8 million and $26,000 associated with the proposed settlement with the SEC for the second and third quarters of 2015, respectively. The present estimated settlement expense, which totals $12 ,826,000 , may be subject to change based on the results of any final settlement with the SEC relating to these matters; it may also be subject to change based on the results of settlement discussions with the DOJ related to its separate investigation. Monetary losses could be materially different than the $12,826,000 presently accrued; however, any such amounts cannot be reasonably estimated given they are substantially dependent on further discussion and negotiation. NovaMed was a party to a Distribution and Supply Agreement with MEDA Pharma GmbH & Co. KG (“MEDA”). Following the Company’s acquisition of NovaMed, MEDA claimed it had a right to terminate the agreement under a change of control provision. NovaMed does not believe that MEDA had a right of termination under the agreement. NovaMed filed an application for binding arbitration with the China International Economic and Trade Arbitration Commission (“CIETAC”) on July 26, 2012. On April 3, 2014, CIETAC issued the final Award of the Arbitral Tribunal. The Arbitral Tribunal found that MEDA did have a right to terminate the agreement upon a change of control, but that MEDA must make reasonable reimbursement to NovaMed before any product rights are returned to MEDA. The amount that must be paid includes $333,333 as “unjust enrichment” plus an amount for reasonable compensation for such services provided by NovaMed to MEDA. The amount of such payment for services was not determined by the Arbitral Tribunal, but was left to be determined by NovaMed. On April 30, 2014, NovaMed informed MEDA that its determination of reasonable compensation for its services was $3,314,629 , including the $333,333 for unjust enrichment. MEDA made a counter offer and the parties were attempting to resolve the matter without an additional arbitration proceeding. I n December 2014, NovaMed filed a “Request for Second Arbitration” with CIETAC in order to enforce its right to compensation. The arbitration case is pending with CIETAC and no hearing has taken place yet. T he amount of any final payment to NovaMed remains uncertain , and as such the Company has not recognized it as a gain contingency . Purchase Obligations Under agreements with certain of the Company’s pharmaceutical partners, the Company is committed to certain annual minimum product purchases where the contract is subject to termination if the annual minimum order is not met. As of September 30, 2015, the Company did not have any material unmet purchase obligations.

Development And Commercializati

Development And Commercialization Agreement	9 Months Ended
	Sep. 30, 2015
Development And Commercialization Agreement [Abstract]
Development And Commercialization Agreement	Note 10 — Development and Commercialization Agreement In May 2015, Theravance Biopharma, Inc. (“Theravance Biopharma”) granted the Company exclusive development and commercialization rights to VIBATIV ® (telavancin) in China, as well as the Hong Kong SAR, the Macau SAR, Taiwan and Vietnam, in exchange for upfront and regulatory milestone payments totaling $6 million. SciClone will be responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration. Theravance Biopharma will sell to SciClone all clinical and commercial product required to develop and commercialize VIBATIV in China and the Company’s other licensed territories. For the three- and nine-months ended September 30, 2015, the Company recognized $0 and $5.5 million, respectively, in research and development expenses related to its new in-license arrangements, primarily with Theravance Biopharma. There was no similar expense recognized in the three- and nine-month periods ended September 30, 2014.

Termination of Collaboration wi

Termination of Collaboration with Cardiome Pharma Corp. (“Cardiome”)	9 Months Ended
	Sep. 30, 2015
Termination Of Collaboration With Cardiome Pharma Corp. (“Cardiome”) [Abstract]
Termination Of Collaboration With Cardiome Pharma Corp. (“Cardiome”)	Note 11 — Termination of Collaboration with Cardiome Pharma Corp. (“Cardiome”) In August 2015, Cardiome, from whom the Company licensed marketing and commercialization rights to the heart medication Aggrastat ® , and the Company mutually agreed to end their collaboration for Aggrastat and terminate the Company’s exclusive distributorship in China for the product, resulting in the Company’s obligation to return all rights to the product to Cardiome. The Company recorded Aggrastat revenues of $1.8 million and $1.3 million for the nine months ended September 30, 2015 and 2014, respectively, and the Company does not expect to generate any further Aggrastat revenues. The terms of the agreement include up to $750,000 in transition payments to be received by the Company from Cardiome over approximately a one year period and require Cardiome to repurchase Aggrastat inventory held by the Company at its original purchase price. Transition payments in the amount of $150,000 were collected from Cardiome during the quarter ended September 30, 2015 and were recorded as a credit to general and administrative expenses. Since the Company had previously written down some of the Aggrastat inventory prior to December 31, 2014 to a substantially lower amount based upon lower-than-expected demand, it was concluded that the remaining inventory as of September 30, 2015 was appropriately stated. There have been no inventory repurchases by Cardiome to date; assuming such repurchases do occur and cash is received, the Company expects to record any excess of repurchase price over inventory cost basis as a reduction to cost of sales. For the three and nine-month periods ended September 30, 2015, the Company recorded a liability of $0.6 million, and a corresponding offset to revenue and cost of goods sold, related to Aggrastat product it expects to repurchase from its customer in connection with the termination of its agreement with Cardiome.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Taxes [Abstract]
Income Taxes	Note 12 — Income Taxes The provision for income taxes primarily relates to taxable income of the Company’s China operations. The Company recorded income tax expense of $0.6 million and $0.3 million for the three months ended September 30, 2015 and 2014, respectively. The increase of $0.3 million in the provision for income tax for the three-month period ended September 30, 2015, compared to the same period of the prior year, mainly related to increased taxable income related to growth in the Company’s China operations. The provision for income tax was $0.6 million and $ 0.8 million for the nine-month periods ended September 30, 2015 and 2014, respectively. The decrease of $0.2 million in the provision for income tax for the nine-month period ended September 30, 2015, compared to the same period of the prior year, mainly related to a reduction in the Company’s liabilities for uncertain tax positions in China due to certain tax years becoming closed to assessment due to the statute of limitations. The Company’s statutory tax rate in China was 25% in 2015 and 2014. The Company has not recorded any significant US federal or state income taxes for the three- and nine-month periods ended September 30, 2015 and 2014. Subsequent to September 30, 2015, the Company repatriated a special dividend distribution of $12,826,000 from its foreign subsidiary as a result of the estimated settlement expense (as previously described in Note 9) from the current year earnings and profits of its foreign subsidiaries, which were not part of the cumulative pool of undistributed earnings of foreign subsidiaries as of December 31, 2014. Additionally, the Company determined that as of September 30, 2015, $162.4 million of accumulated undistributed earnings of foreign subsidiaries, exclusive of the dividend repatriation which was entirely satisfied out of current year earnings and profits, continues to be indefinitely reinvested outside of the US. Based upon its current year actual results and projections of tax deductible corporate expenses and other offsetting factors, the Company does not expect that the dividend income or the nondeductible estimated settlement expense will lead to any incremental US income tax liability. Upon distribution of its foreign undistributed earnings, the Company may be subject to US federal and state income taxes, although determining the amount of tax liability is not practicable as it is dependent on a variety of factors, including but not limited to the amounts of US tax loss carryforwards and tax credit carryforwards available at the time of the repatriation. Based on the Company’s current operating plan, it does not anticipate the need to repatriate cash and cash equivalents held by foreign subsidiaries in the foreseeable future, other than amounts already repatriated related to the estimated settlement expense. However, the Company has not yet reached a resolution of these matters with the DOJ. Should undistributed earnings need to be remitted, the Company will accrue for income taxes not previously recognized.

Segment Information And Geograp

Segment Information And Geographic Data	9 Months Ended
	Sep. 30, 2015
Segment Information And Geographic Data [Abstract]
Segment Information And Geographic Data	Note 13 — Segment Information and Geographic Data The Company reports segment information based on the internal reporting used by management for evaluating segment performance based on management’s estimates of the appropriate allocation of resources to segments. T he Company operates and manages its business primarily on a geographic basis. Accordingly, the Company determined its operating segments and reporting units, which are generally based on the nature and location of its customers, to be 1) China, and 2) Rest of the World, including the US and Hong Kong. The Company evaluates the performance of its operating segments based on revenues and operating income. Revenues for geographic segments are generally based on the location of customers. Operating income for each segment includes revenues, related cost of sales and operating expenses directly attributable to the segment. Operating income for each segment excludes non-operating income and expense. Summary information by operating segment for the three- and nine-month periods ended September 30, 2015 and 2014 is as follows ( in thousands ): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Revenue: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total net revenues $ $ $ $ Income (loss) from operations: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total income from operations $ $ $ $ Non-operating income (expense), net: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total non-operating income (expense), net $ $ $ $ Income before provision for income tax: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total income before provision for income tax $ $ $ $ Long-lived assets as of September 30, 2015 by operating segment are as follows ( in thousands ): China $ Rest of the World (including the US and Hong Kong) $

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2015
Subsequent Event [Abstract]
Subsequent Event	Note 14 — Subsequent Event On October 7, 2015, the Company deposited $12,826,000 in an interest-bearing escrow account that it established related to the agreement in principle regarding a proposed settlement of FCPA-related matters with the staff of the SEC as further discussed in Note 9. The escrow funds, which created a cash restriction when they were deposited, are to be distributed from the escrow account upon approval of the offer of settlement, which is subject to review by the Commissioners of the SEC.

Basis Of Presentation (Policy)

Basis Of Presentation (Policy)	9 Months Ended
	Sep. 30, 2015
Basis Of Presentation [Abstract]
Basis Of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the audited consolidated financial statements and the notes thereto for the year ended December 31, 2014 included in the Company’s Form 10-K as filed with the US Securities and Exchange Commission (“SEC”). The Company prepared the unaudited condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other information that are normally required by GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The interim financial information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited condensed consolidated balance sheet data as of December 31, 2014 is derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ significantly from those estimates.
Revisions	Revisions The Company reduced the line item “Inventories” and increased the line item “Provision for expiring inventory” in the amount of $0.4 million within the reconciling adjustments in its condensed consolidated statement of cash flows for the nine months ended September 30, 2014 to correct an error in the prior year presentation. This revision had no impact on cash provided by operating activities. For the full year 2014, the line item “Inventories” was overstated and the line item “Provision for expiring inventory” was understated by $0.5 million within the reconciling adjustments in its consolidated statement of cash flows as presented for the year ended December 31, 2014 included in the Company’s Form 10-K as filed with the SEC. The amounts of the errors are not material to the annual or interim periods of 2014.
Customer Concentration	Customer Concentration In China, pharmaceutical products are imported and distributed through a tiered method of distribution. For the Company’s proprietary product ZADAXIN ® , the Company manufactures its product using its US and European contract manufacturers, and it generates its product sales revenue through sales of ZADAXIN products to Sinopharm Holding Hong Kong Co. Ltd. (“Sinopharm”). Sinopharm and its affiliates act as an importer, and also as the top “tier” of the distribution system (“Tier 1”) in China. The Company’s ZADAXIN sales occur when the importer purchases product from the Company, without any right of return except for damaged product or quality control issues and passage of title and risk of loss are transferred to Sinopharm at the time of shipment. After the Company’s sale of ZADAXIN to the importer, Sinopharm clears products through China import customs, sells directly to large hospitals and holds additional product it has purchased in inventory for sale to the next tier in the distribution system. The second-tier (“Tier 2”) distributors are responsible for the further sale and distribution of the products they purchase from the importer, either through sales of product directly to the retail level (hospitals and pharmacies), or to third-tier (“Tier 3”) local or regional distributors who, in turn, sell products to hospitals and pharmacies. The Company’s other product sales revenues result from the sale of the Company’s in-licensed products to importing agents and distributors. Promotion services revenues result from fees received for exclusively promoting products for certain pharmaceutical partners. These importing agents, distributors and partners are the Company’s customers. Sinopharm revenues relate to the Company’s China segment. Sinopharm contributed 98% and 94% of the Company’s total net revenue for the three-month periods ended September 30, 2015 and 2014, respectively. Sinopharm contributed 92% and 93% of the Company’s total net revenue for the nine-month periods ended September 30, 2015 and 2014, respectively. There were no other customers that exceeded 10% of the Company’s total net revenue in the periods presented. As of September 30, 2015, approximately $ 37.4 million, or 91% , of the Company's accounts receivable was attributable to one customer, Sinopharm, in China. The Company generally does not require collateral from its customers.
Accounts Receivable Reserve	Accounts Receivable Receivable Reserve. The Company records a receivable reserve based on a specific review of its overdue invoices. The Company’s estimate for a reserve is determined after considering its existing contractual payment terms, payment patterns of its customers and individual customer circumstances, the age of any outstanding receivables and its current customer relationships. Accounts receivable are written off at the point when they are considered uncollectible. As of September 30, 2015, the Company had a receivable reserve of $1.1 million. The reserve includes $0.5 million from one customer that is more than one year past due. In October 2014, the Company’s subsidiary, SciClone Pharmaceuticals International China Holding Ltd (“SPIL China”) executed an agreement with this particular customer providing for settlement of the receivable balance, which at the time was $1.9 million, of which $1.0 million was paid in 2014. The remaining $0.9 million was scheduled to be paid in installments as follows: (i) $0.4 million before May 31, 2015, and (ii) $0.5 million by December 31, 2015. The Company collected $0.4 million in May 2015, and this gain on recovery was recorded as a $0.4 million reduction to general and administrative expense for the nine-month period ended September 30, 2015. The Company will continue to maintain a full reserve on the remaining $0.5 million outstanding accounts receivable balance from this customer until payment is received. As of September 30, 2015, the Company had $0.5 million in fully reserved accounts receivable from another customer that are past due. The Company recognized $0.5 million of bad debt expense in general and administrative expense during the first quarter of 2015 due to uncertainty regarding the collectability of the customer’s outstanding receivable balance.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, services have been rendered or delivery has occurred, the price to the buyer is fixed or determinable and collectability is reasonably assured. Product Revenue . The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN to Sinopharm and its affiliates are recognized at time of shipment when title to the product is transferred to them. The Company also earns product revenue from purchasing medical products from pharmaceutical companies and selling them directly to importers or distributors. The Company recognizes revenue related to these products based on the “sell-in” method, when the medical products have been delivered to the importers or distributors. Payments by the importing agents and distributors are not contingent upon sale to the end user by the importing agents or distributors. Promotion Services Revenue . The Company recognizes promotion services revenue after designated medical products are delivered to the distributors as specified in a promotion services contract, which marks the period when marketing and promotion services have been rendered and the revenue recognition criteria are met. Revenue Reserve. The Company generally maintains a revenue reserve for product returns based on estimates of the amount of product to be returned by its customers which may result from expired or damaged product on delivery, and is based on historical patterns, analysis of market demand and/or a percentage of sales based on industry trends, and management’s evaluation of specific factors that may increase the risk of product returns. Importing agents or distributors do not have contractual rights of return except under limited terms regarding product quality. However, the Company is expected to replace products that have expired or are deemed to be damaged or defective when delivered. The calculation of the revenue reserve requires estimates and involves a high degree of subjectivity and judgment. As a result of the uncertainties involved in estimating the revenue reserve, there is a possibility that materially different amounts could be reported under different conditions or using different assumptions. As of September 30, 2015 and December 31, 2014, the Company’s revenue reserves were $0.6 million and $0. 1 million, respectively.
Inventories	Inventories Inventories consist of raw materials, work in progress and finished products. Inventories are valued at the lower of cost or market (net realizable value), with cost determined on a first-in, first-out basis, and include amounts related to materials, labor and overhead. The Company periodically reviews the inventory in order to identify excess and obsolete items, including pharmaceutical products approaching their expiration dates. If obsolete or excess items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value. For the three- and nine-month periods ended September 30, 2015, the Company recorded no inventory write-downs. For the three- and nine-month periods ended September 30, 2014, the Company recorded inventory write-downs of $0.6 million and $1.0 million, respectively, related to carrying value reductions for excess Aggrastat ® product.
Loans Receivable	Loans Receivable Loans receivable are due from a single third party (see Note 4). Loans are initially recorded, and continue to be carried, at unpaid principal balances under “other assets” on the unaudited condensed consolidated balance sheet. Carried balances are subsequently adjusted for payments of principal or adjustments to the allowance for loan losses to account for any impairment. Interest income is recognized over the term of the loans and is calculated using the simple-interest method, as the loans do not have associated premium or discount. If the loans were to experience impairment, interest income would not be recognized unless the likelihood of further loss was remote. Although the measurement basis is unpaid principal (as adjusted for subsequent payments or impairment), not fair value, the loans receivable would qualify as Level 3 measurements under the fair value hierarchy (Note 2) due to the presence of significant unobservable inputs related to the counterparty, which is a private entity. Management considers impairment to exist when, based on current information or factors (such as payment history, value of collateral, and assessment of the counterparty’s current creditworthiness), it is probable that principal and interest payments will not be collected according to the contractual agreements. Management considers a loan payment delinquent when not received by the due date. As of September 30, 2015 and December 31, 2014, management concluded the loans receivable were not impaired, and there was no allowance for loan losses.
Net Income Per Share	Net Income Per Share Basic net income per share has been computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted net income per share is computed by dividing net income by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income per share includes any dilutive impact from outstanding stock options, restricted stock units (RSUs), performance restricted stock units (PSUs) and the employee stock purchase plan using the treasury stock method. The following is a reconciliation of the numerator and denominators of the basic and diluted net income per share computations (in thousands, except per share amounts): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Numerator: Net income $ $ $ $ Denominator: Weighted-average shares outstanding used to compute basic net income per share Effect of dilutive securities Weighted-average shares outstanding used to compute diluted net income per share Basic net income per share $ $ $ $ Diluted net income per share $ $ $ $ For the three months ended September 30, 2015 and 2014, outstanding stock options for 1,514,534 and 3,733,555 shares, respectively, were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options calculated under the treasury stock method would have been anti-dilutive. In addition, for the three months ended September 30, 2015 and 2014, outstanding stock options and awards for 312,500 and 50,000 shares, respectively, subject to performance conditions were excluded from the calculation of diluted net income per share because the performance criteria had not been met. For the nine months ended September 30, 2015 and 2014, outstanding stock options for 1,043,815 and 3,924,745 shares, respectively, were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options calculated under the treasury stock method would have been anti-dilutive. In addition, for the nine months ended September 30, 2015 and 2014, outstanding stock options and awards for 325,137 and 50,000 shares, respectively, subject to performance conditions were excluded from the calculation of diluted net income per share because the performance criteria had not yet been met.
New Accounting Standards Update	New Accounting Standards Updates In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 is effective for the Company’s fiscal year beginning January 1, 2018, which reflects a one year deferral approved by the FASB in July 2015, with early application permitted provided that the effective date is not earlier than the original effective date. The Company is in the process of determining what impact, if any, the adoption of ASU 2014-09 will have on its financial statements and related disclosures. The standard permits the use of either the full retrospective or modified retrospective transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In July 2015, the FASB issued ASU 2015-11, " Inventory (Topic 330): Simplifying the Measurement of Inventory " (“ASU 2015-11”) which applies to inventory that is measured using first-in, first-out ("FIFO") or average cost. Under the updated guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory that is measured using last-in, first-out ("LIFO"). This ASU is effective for annual and interim periods beginning after December 15, 2016, and should be applied prospectively with early adoption permitted at the beginning of an interim or annual reporting period. The Company has evaluated the impact of adopting this guidance and has concluded it will likely have minimal effect on the financial statements as the Company already applies the concept of net realizable value; moreover, inventory provisions are generally full write-downs for the affected inventory.

Basis Of Presentation (Tables)

Basis Of Presentation (Tables)	9 Months Ended
	Sep. 30, 2015
Basis Of Presentation [Abstract]
Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income (Loss) Per Share Computations	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Numerator: Net income $ $ $ $ Denominator: Weighted-average shares outstanding used to compute basic net income per share Effect of dilutive securities Weighted-average shares outstanding used to compute diluted net income per share Basic net income per share $ $ $ $ Diluted net income per share $ $ $ $

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Financial Assets And Liability Measured At Fair Value On A Recurring Basis	Fair Value Measurements as of September 30, 2015 Using Quoted Prices in Significant Active Markets Other Significant for Observable Unobservable Balance Identical Assets Inputs Inputs as of Description (Level 1) (Level 2) (Level 3) September 30, 2015 Money market funds $ $ — $ — $ Total $ $ — $ — $ Fair Value Measurements as of December 31, 2014 Using Quoted Prices in Significant Active Markets Other Significant for Observable Unobservable Balance Identical Assets Inputs Inputs as of Description (Level 1) (Level 2) (Level 3) December 31, 2014 Certificate of deposit $ — $ $ — $ Money market funds — — Total $ $ $ — $

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2015
Inventories [Abstract]
Schedule Of Inventories	September 30, December 31, 2015 2014 Raw materials $ $ Work in progress Finished goods $ $

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill [Abstract]
Schedule Of Changes In Goodwill	Balance as of December 31, 2014 $ Translation adjustments Balance as of September 30, 2015 $

Accrued And Other Current Lia26

Accrued And Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued And Other Current Liabilities [Abstract]
Schedule Of Accrued And Other Current Liabilities	September 30, December 31, 2015 2014 Accrued estimated settlement expense (Note 9) $ $ Accrued sales and marketing expenses Accrued taxes, tax reserves and interest Accrued compensation and benefits Accrued professional fees Accrued manufacturing costs Accrued license fee — Other $ $

Accumulated Other Comprehensi27

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Schedule Of Changes In The Composition Of Accumulated Other Comprehensive Income	Balances as of July 1, 2015 $ Other comprehensive loss related to foreign currency translation Balances as of September 30, 2015 $ Balances as of July 1, 2014 $ Other comprehensive income related to foreign currency translation Balances as of September 30, 2014 $ Balances as of January 1, 2015 $ Other comprehensive loss related to foreign currency translation Balances as of September 30, 2015 $ Balances as of January 1, 2014 $ Other comprehensive loss related to foreign currency translation Balances as of September 30, 2014 $

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Stock-Based Compensation Expenses Included In The Condensed Consolidated Statements Of Operations	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Sales and marketing $ $ $ $ Research and development General and administrative $ $ $ $

Segment Information And Geogr29

Segment Information And Geographic Data (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Information And Geographic Data [Abstract]
Summary Information By Operating Segment	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Revenue: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total net revenues $ $ $ $ Income (loss) from operations: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total income from operations $ $ $ $ Non-operating income (expense), net: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total non-operating income (expense), net $ $ $ $ Income before provision for income tax: China $ $ $ $ Rest of the World (including the US and Hong Kong) Total income before provision for income tax $ $ $ $
Long-Lived Assets By Operating Segment	China $ Rest of the World (including the US and Hong Kong) $

Basis Of Presentation (Narrativ

Basis Of Presentation (Narrative) (Details)	1 Months Ended			3 Months Ended			9 Months Ended		12 Months Ended
	Dec. 31, 2015USD ($)	May. 31, 2015USD ($)	Oct. 31, 2014USD ($)	Sep. 30, 2015USD ($)shares	Mar. 31, 2015USD ($)	Sep. 30, 2014USD ($)shares	Sep. 30, 2015USD ($)customershares	Sep. 30, 2014USD ($)shares	Dec. 31, 2014USD ($)
Basis of Presentation [Line Items]
Reclassification adjustment								$ 400,000	$ 500,000
Allowance for doubtful accounts				$ 1,137,000			$ 1,137,000		998,000
General and administrative				7,290,000		$ 5,611,000	21,410,000	17,460,000
Product returns reserve amount							600,000		100,000
Write-downs related to inventory								$ 990,000
Allowance for loan losses				0			0		0
One Customer [Member]
Basis of Presentation [Line Items]
Accounts receivable gross				900,000			900,000
Settlement between customer and company			$ 1,900,000
Proceeds from settlement between customer and company									$ 1,000,000
Additional Customer [Member]
Basis of Presentation [Line Items]
Allowance for doubtful accounts				$ 500,000			$ 500,000
General and administrative					$ 500,000
Sinopharm [Member] | Sales Revenue, Net [Member]
Basis of Presentation [Line Items]
Concentration percentage				98.00%		94.00%	92.00%	93.00%
Sinopharm [Member] | Accounts Receivable [Member]
Basis of Presentation [Line Items]
Concentration percentage							91.00%
Accounts receivable gross				$ 37,400,000			$ 37,400,000
Number of customers | customer							1
Aggrastat Product Sales [Member]
Basis of Presentation [Line Items]
Product returns reserve amount				$ 600,000			$ 600,000
Write-downs related to inventory						$ 600,000		$ 1,000,000
Stock Options And Awards [Member]
Basis of Presentation [Line Items]
Shares excluded from the calculation of diluted net income (loss) per share | shares				1,514,534		3,733,555	1,043,815	3,924,745
Stock Options And Awards Subject To Performance Conditions [Member]
Basis of Presentation [Line Items]
Shares excluded from the calculation of diluted net income (loss) per share | shares				312,500		50,000	325,137	50,000
SPIL China [Member] | One Customer [Member]
Basis of Presentation [Line Items]
Allowance for doubtful accounts				$ 500,000			$ 500,000
Number of customers | customer							1
Period past due							1 year
Allowance for doubtful accounts, collected		$ 400,000					$ 400,000
General and administrative							$ (400,000)
SPIL China [Member] | Scenario, Forecast [Member] | One Customer [Member]
Basis of Presentation [Line Items]
Allowance for doubtful accounts, collected	$ 500,000

Basis Of Presentation (Reconcil

Basis Of Presentation (Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income (Loss) Per Share Computations) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Basis Of Presentation [Abstract]
Net income	$ 11,979	$ 7,915	$ 16,919	$ 21,689
Weighted-average shares outstanding used to compute basic net income per share	49,869	51,032	49,920	51,533
Effect of dilutive securities	2,257	1,361	2,424	1,266
Weighted-average shares outstanding used to compute diluted net income per share	52,126	52,393	52,344	52,799
Basic net income per share	$ 0.24	$ 0.16	$ 0.34	$ 0.42
Diluted net income per share	$ 0.23	$ 0.15	$ 0.32	$ 0.41

Fair Value Measurements (Financ

Fair Value Measurements (Financial Assets And Liability Measured At Fair Value On A Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	$ 19,678	$ 19,753
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	19,678	19,678
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value		75
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value		75
Certificates of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value		75
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	19,678	19,678
Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value	$ 19,678	$ 19,678

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 5,219	$ 5,009
Work in progress	486	761
Finished goods	6,442	4,933
Inventories	12,147	10,703
Inventory held at distributors	$ 3,600	$ 3,100

Loans Receivable (Details)

Loans Receivable (Details) ¥ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended			12 Months Ended
	May. 31, 2013USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015CNY (¥)loan	Sep. 30, 2015USD ($)loan	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)loan	Jun. 30, 2015USD ($)	Sep. 30, 2014CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Commitment agreement, number of loan agreements | loan				2	2		2
Interest and investment income		$ 252,000	$ 31,000		$ 614,000	$ 73,000
Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collateralized loan amount, maximum	$ 12,000,000
Allowance for loan losses					0		$ 0
SPIL China [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collateralized loan amount, maximum					11,750,000
Loan receivable		$ 11,750,000			$ 11,750,000
Interest rate		7.50%			7.50%
Expiration date				Sep. 26, 2017	Sep. 26, 2017
Collateralized loan, option to extend, period				2 years	2 years
SciClone Pharmaceuticals (China) Ltd [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collateralized loan amount, maximum | ¥				¥ 1,550
Loan receivable		$ 244,000			$ 244,000				¥ 1,550
Interest rate		7.50%			7.50%
Term				66 months	66 months
SPIL China and SciClone Pharmaceuticals (China) Ltd [Member
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest and investment income		$ 200,000			$ 500,000
Loan One [Member] | Zensun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable		$ 12,000,000			$ 12,000,000
Loan One [Member] | SPIL China [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable							$ 4,500,000
Loan Two [Member] | SPIL China [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable								$ 7,250,000

Goodwill (Schedule Of Changes I

Goodwill (Schedule Of Changes In Goodwill) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Abstract]
Beginning balance	$ 34,521
Translation adjustments	(835)
Ending balance	$ 33,686

Accrued And Other Current Lia36

Accrued And Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accrued And Other Current Liabilities [Abstract]
Accrued estimated settlement expense (Note 9)	$ 12,826	$ 2,000
Accrued sales and marketing expenses	8,740	5,383
Accrued taxes, tax reserves and interest	4,355	5,208
Accrued compensation and benefits	3,591	4,176
Accrued professional fees	1,716	1,819
Accrued manufacturing costs	537	95
Accrued license fee		1,000
Other	423	855
Accrued and other current liabilities, total	$ 32,188	$ 20,536

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Schedule Of Changes In The Composition Of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income [Abstract]
Foreign Currency Translation, Beginning balance	$ 3,307	$ 3,402	$ 3,264	$ 4,176
Other comprehensive income (loss) related to foreign currency translation	(661)	308	(618)	(466)
Foreign Currency Translation, Ending balance	$ 2,646	$ 3,710	$ 2,646	$ 3,710

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchased and retired, shares | shares		1,526,306
Stock repurchased and retired, value		$ 12,800
Share repurchase program, remaining amount authorized	$ 2,400	2,400
Share repurchase program, amount authorized	80,500	$ 80,500
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, options granted, shares | shares		1,375,500
Common stock, option exercises, shares | shares		868,682
Unrecognized compensation expense, net of forfeitures	6,400	$ 6,400
Unrecognized compensation expense, weighted-average remaining period for recognition, in years		2 years 7 months 6 days
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options per share | $ / shares		$ 8.95
RSUs granted, shares | shares		388,000
RSUs vested, shares | shares		105,517
PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, options granted, shares | shares		300,000
Weighted average grant date fair value of options per share | $ / shares		$ 8.95
Share based compensation costs	31	$ 60
RSUs and PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, net of forfeitures	$ 2,500	$ 2,500
Unrecognized compensation expense, weighted-average remaining period for recognition, in years		2 years 4 months 6 days

Stockholders' Equity (Stock-Bas

Stockholders' Equity (Stock-Based Compensation Expenses Included In The Condensed Consolidated Statements Of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	$ 1,361	$ 834	$ 3,437	$ 2,609
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	217	276	685	761
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	65	19	159	78
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses recognized	$ 1,079	$ 539	$ 2,593	$ 1,770

Commitments And Contingencies (

Commitments And Contingencies (Details) - USD ($)	Apr. 30, 2014	Apr. 03, 2014	Sep. 30, 2015	Jun. 30, 2015	Dec. 31, 2013	Sep. 30, 2015
Contingencies and Commitments [Line Items]
Loss contingency, disgorgement			$ 9,400,000			$ 9,400,000
Loss contingency, prejudgement interest			900,000			900,000
Loss contingency, civil money penalty			2,500,000			2,500,000
Probable payment to government in penalties, fines and/or other remedies					$ 2,000,000
Loss contingency, estimated loss			12,826,000			12,826,000
Estimated settlement expense (Note 9)			$ 26,000	$ 10,800,000		$ 10,826,000
NovaMed [Member]
Contingencies and Commitments [Line Items]
Reimbursement for unjust enrichment		$ 333,333
Determination of reasonable compensation for services provided, including unjust enrichment	$ 3,314,629

Development And Commercializa41

Development And Commercialization Agreement (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 31, 2015
Research and development expense	$ 0	$ 0	$ 5,500,000	$ 0
Theravance Biopharma [Member]
Upfront and regulatory milestone payments					$ 6,000,000

Termination Of Collaboration 42

Termination Of Collaboration With Cardiome Pharma Corp. (“Cardiome”) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Revenues	$ 42,880,000	$ 34,287,000	$ 114,394,000	$ 93,365,000
Transition payments to be received	750,000		750,000
Transition payments received	150,000
Inventory repurchases			0
Product returns reserve amount			600,000		$ 100,000
Aggrastat Product Sales [Member]
Revenues			1,800,000	$ 1,300,000
Product returns reserve amount	$ 600,000		$ 600,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Line Items]
Provision for income tax		$ 587,000	$ 331,000	$ 611,000	$ 763,000
Increase (decrease) in tax expense		300,000		(200,000)
Undistributed earnings of foreign subsidiaries		$ 162,400,000		$ 162,400,000
Subsequent Event [Member]
Income Tax Disclosure [Line Items]
Special dividend distribution repatriated from foreign subsidiary	$ 12,826,000
China [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate				25.00%	25.00%

Segment Information And Geogr44

Segment Information And Geographic Data (Summary Information By Operating Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 42,880	$ 34,287	$ 114,394	$ 93,365
Income (loss) from operations	12,595	8,107	17,221	22,408
Non-operating income (expense), net	(29)	139	309	44
Income before provision for income tax	12,566	8,246	17,530	22,452
China [Member]
Segment Reporting Information [Line Items]
Revenue	40,676	33,168	109,388	90,134
Income (loss) from operations	14,649	10,478	34,650	29,499
Non-operating income (expense), net	(44)	144	288	57
Income before provision for income tax	14,605	10,622	34,938	29,556
Rest Of The World (Including The U.S. And Hong Kong) [Member]
Segment Reporting Information [Line Items]
Revenue	2,204	1,119	5,006	3,231
Income (loss) from operations	(2,054)	(2,371)	(17,429)	(7,091)
Non-operating income (expense), net	15	(5)	21	(13)
Income before provision for income tax	$ (2,039)	$ (2,376)	$ (17,408)	$ (7,104)

Segment Information And Geogr45

Segment Information And Geographic Data (Long-Lived Assets By Operating Segment) (Details) $ in Thousands	Sep. 30, 2015USD ($)
Segment Reporting Information [Line Items]
Long-lived assets	$ 48,412
China [Member]
Segment Reporting Information [Line Items]
Long-lived assets	47,163
Rest Of The World (Including The U.S. And Hong Kong) [Member]
Segment Reporting Information [Line Items]
Long-lived assets	$ 1,249

Subsequent Event (Details)

Subsequent Event (Details)	Oct. 07, 2015USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Escrow deposit	$ 12,826,000